Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,671.69
(
-0.66%
)
US TECH 100
23,984.00
(
-0.61%
)
Dow Jones
46,577.63
(
-0.88%
)
Brent Oil
106.41
(
5.72%
)
Bitcoin
71,534.43
(
-3.26%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 88597

Wednesday, 01/13/2010 2:30:04 AM

Wednesday, January 13, 2010 2:30:04 AM

Post# of 257253
PFE’s most promising late-stage candidates, according to the company itself:

• Tanezumab for osteoarthritis
• CP-690,550 (JAK3 inhibitor) for RA
• Dimebon for AD
• Bapineuzumab for AD
• PF-2341066 (cMET inhibitor) for NSCLC

http://www.reuters.com/article/idCNN1212877120100112


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now